Plain-English translation of NCT05831865 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether stem cell transplantation, combined with chemotherapy, can help people with a high-risk type of lymphoma called diffuse large B-cell lymphoma. You would first receive standard chemotherapy (called R-CHOP), and then doctors would collect your own stem cells and transplant them back into your body to help it recover. The goal is to see if this approach stops the cancer from coming back better than chemotherapy alone.
Doctors believe that combining chemotherapy with stem cell transplant early in treatment might work better for people with high-risk lymphoma, but they're still uncertain because the procedure carries risks. This trial will measure whether this combination approach is actually more effective and safe for patients who need it most.
You likely qualify if…
You likely don't qualify if…
You would start with standard chemotherapy (R-CHOP), then have imaging scans to see how well the cancer is responding. If your cancer responds well, you would receive a stem cell transplant and be followed for up to two years. If your cancer only partially responds, you may receive additional chemotherapy before the transplant. Throughout the trial, you would have regular doctor visits, scans, and blood tests to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Sponsor
Peking University People's Hospital
Collaborators
Peking University Cancer Hospital & Institute
Enrollment target
~175 participants
Started
May 2023
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xuelin Dou, M.D.
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.